17,261 trials
Atherosclerosis
Primary: Change From Baseline of Mean of Maximum Tissue to Background Ratio (TBR) in the Qualifying Artery, Following 12 Weeks of Treatment in the Setting of Chronic Statin…
HIV Infections
Primary: Number of Participants With Serious Adverse Event — 0; 0 Participants
Non Small Cell Lung Cancer
Primary: Disease Control Rate (DCR) — 63.3 percentage of participants
Kidney Failure, Acute · Renal Replacement Therapy
Primary: Number of Participants Who Developed Acute Kidney Injury Within 72 Hours — 17; 14 Participants
Multiple Myeloma
Primary: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria — 0.0 percentage of participants
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Percentage of Patients With Objective Tumor Response Rate (Either Complete Response (CR) or Partial Response (PR) Using RECIST Version 1.0 — 8 Percentage of participants
Prostatic Neoplasms · Prostate Cancer · Neoplasm, Prostate
Primary: Progression Free Survival (PFS) — 2.8; 9.0; 11.5; 10.1 Months — p=0.44
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Percentage of Patients Who Survive Progression-free — 11.5 percentage of participants
Malignant Peritoneal Mesothelioma
Primary: Objective Response Rate
Melanoma (Skin)
Primary: Tumor Response Rate, as Measured by RECIST Criteria — 8.8; 25.6 percentage of participants
Carcinoma, Non-Small-Cell Lung · Adenocarcinoma
Primary: Progression-free Survival (PFS) — 5.2; 7.2 weeks
Recurrent Osteosarcoma
Primary: Disease Control Success — 3 Participants
Metachromatic Leukodystrophy (MLD)
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Type and Severity — 6; 6; 6; 6 Participants
Multiple Myeloma
Primary: Progression Free Survival (PFS) — 17; 25; 19 Participants
Hepatitis C, Chronic
Primary: Proportion of Subjects Achieving Sustained Viral Response at 12 Weeks After the End of Treatment. — 11; 10 Participants